Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From WuXi AppTec
Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.
Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.
Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.
Having been used to navigating the Pacific with few obstacles, biotech companies taking advantage of Chinese resources and US innovation now face ballooning tensions between the two countries, which along with narrowing funding channels will increasingly force them to decide where to place their bets in the world’s largest economies.
- Contract Research Organization-CRO
- Laboratory Testing Services
- Medical Devices
Drug Discovery Technologies
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Crelux GmbH
- Faxian Therapeutics
- JW Biotechnology (Shanghai) Co., Ltd
- ResearchPoint Global
- STA Pharmaceutical Co., Ltd.
- WuXi PharmaTech
- WuXi Merger Limited
- XenoBiotic Laboratories, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.